Harrow Inc (HROW)

$33.28 -1.13 (-3.28%)
Market Cap 1.28B
Revenue (ttm) 272.30M
Net Income (ttm) -5.14M
EPS (ttm) N/A
PE Ratio 76.62
Forward PE 37.08
Profit Margin -1.89%
Debt to Equity Ratio 4.67
Volume 1,010,100
Avg Vol 758,734
Day's Range N/A - N/A
Shares Out 37.23M
Stochastic %K 6%
Beta 0.05
Analysts Strong Sell
Price Target $68.43

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
HubAllianceModern
HubAllianceModern Mar. 21 at 6:30 PM
$HROW biotech, just observing calmly.
0 · Reply
Aombeus
Aombeus Mar. 21 at 6:52 AM
$HROW
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 21 at 5:39 AM
$HROW RSI: 13.38, MACD: -3.7069 Vol: 8.36, MA20: 41.00, MA50: 44.58 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
azv134
azv134 Mar. 20 at 9:22 PM
THIS MARKET CRASH IS PERFECT TO MAKE THE FOLLOWING STOCKS MY CORE POSITIONS IN 2026 $ABEO $HROW $AQST $OCUL Aiming for ~ 15% allocation of my portfolio in each company.
0 · Reply
Fullback
Fullback Mar. 20 at 8:09 PM
$HROW Still seems to be steady selling pressure. Almost 1M shares traded today, ~ 1/3 of it in the last 1/2hr or so.
1 · Reply
flash9875
flash9875 Mar. 20 at 7:38 PM
$HROW f you trump
0 · Reply
Aombeus
Aombeus Mar. 20 at 7:15 PM
$HROW
0 · Reply
AceBeck
AceBeck Mar. 20 at 1:53 PM
$HROW Oversold?
1 · Reply
Finnish_boy
Finnish_boy Mar. 20 at 11:50 AM
$HROW ETON market cap 550M.. looks nice value. But my other stocks are enough great so i have to look at this later. I almost bought TMDX at $111 but i focus now on my stocks. Have to diversify my portfolio later this year.
0 · Reply
Finnish_boy
Finnish_boy Mar. 20 at 10:06 AM
$HROW HROW and indexes make new ATH by June. HROW and indexes can go couple of percentages lower but bottoms are near. Bears dont understand bigger picture. E.g if you understand NVDA it's super cheap. People talking about bubble is so stupid.
2 · Reply
Latest News on HROW
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Mar 18, 2026, 7:00 AM EDT - 3 days ago

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market

Mar 17, 2026, 2:00 PM EDT - 4 days ago

Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market

These Analysts Revise Their Forecasts On Harrow Following Q4 Results

Mar 4, 2026, 9:07 AM EST - 17 days ago

These Analysts Revise Their Forecasts On Harrow Following Q4 Results

Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

Mar 4, 2026, 7:00 AM EST - 17 days ago

Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade)

Mar 4, 2026, 6:46 AM EST - 17 days ago

Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade)

Harrow, Inc. (HROW) Q4 2025 Earnings Call Transcript

Mar 3, 2026, 5:02 PM EST - 18 days ago

Harrow, Inc. (HROW) Q4 2025 Earnings Call Transcript

Harrow Shares Collapse, Another Opportunity?

Mar 3, 2026, 2:24 PM EST - 18 days ago

Harrow Shares Collapse, Another Opportunity?

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

Mar 3, 2026, 7:00 AM EST - 18 days ago

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

Mar 2, 2026, 4:05 PM EST - 19 days ago

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Feb 18, 2026, 7:00 AM EST - 4 weeks ago

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Feb 17, 2026, 7:00 AM EST - 4 weeks ago

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Feb 2, 2026, 7:00 AM EST - 6 weeks ago

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update

Jan 22, 2026, 6:06 PM EST - 2 months ago

Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update

Harrow: Flirting With Missing 2025 Revised Guidance

Jan 12, 2026, 12:49 PM EST - 2 months ago

Harrow: Flirting With Missing 2025 Revised Guidance

Undercovered Dozen: USA Rare Earth, Santacruz Silver, Western Midstream, Visa And More

Dec 8, 2025, 11:31 AM EST - 3 months ago

Undercovered Dozen: USA Rare Earth, Santacruz Silver, Western Midstream, Visa And More

USAR V WES AGNC AGNCM AGNCN AGNCO

Harrow to Present at Two Investor Conferences in December

Nov 24, 2025, 7:00 AM EST - 4 months ago

Harrow to Present at Two Investor Conferences in December

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Nov 18, 2025, 7:00 AM EST - 4 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 2:11 PM EST - 4 months ago

Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript

Harrow Announces Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 4 months ago

Harrow Announces Third Quarter 2025 Financial Results

Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential

Nov 5, 2025, 12:31 PM EST - 4 months ago

Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other

Oct 15, 2025, 9:03 PM EDT - 5 months ago

Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other

ImprimisRx Announces Leadership Changes

Oct 6, 2025, 7:00 AM EDT - 5 months ago

ImprimisRx Announces Leadership Changes

Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Sep 27, 2025, 12:27 AM EDT - 6 months ago

Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Harrow to Acquire Melt Pharmaceuticals

Sep 26, 2025, 7:00 AM EDT - 6 months ago

Harrow to Acquire Melt Pharmaceuticals

Harrow Launches Harrow Access for All (HAFA)

Sep 25, 2025, 4:05 PM EDT - 6 months ago

Harrow Launches Harrow Access for All (HAFA)

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 15, 2025, 7:00 AM EDT - 6 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Harrow: Buy A Blend Of Value And Growth

Sep 12, 2025, 10:57 AM EDT - 6 months ago

Harrow: Buy A Blend Of Value And Growth

Harrow: A Classical GARP Stock

Sep 9, 2025, 1:11 PM EDT - 6 months ago

Harrow: A Classical GARP Stock

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 5:57 PM EDT - 6 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 14, 2025, 11:09 PM EDT - 7 months ago

Harrow's Ambitious Guidance Puts It In The Proving Ground

Harrow: Exciting Times In Store

Aug 13, 2025, 5:39 PM EDT - 7 months ago

Harrow: Exciting Times In Store

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 2:47 PM EDT - 7 months ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 7 months ago

Harrow Announces Second-Quarter 2025 Financial Results

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 29, 2025, 7:00 AM EDT - 8 months ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 8 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 8 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 15, 2025, 10:38 AM EDT - 8 months ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 11, 2025, 5:47 PM EDT - 9 months ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Harrow: Immense Upside Potential

Jul 9, 2025, 2:52 PM EDT - 9 months ago

Harrow: Immense Upside Potential

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 18, 2025, 7:00 AM EDT - 9 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

I Am Swimming In Dividends With +7% Yields

Jun 13, 2025, 8:30 AM EDT - 10 months ago

I Am Swimming In Dividends With +7% Yields

UMH

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Jun 9, 2025, 7:00 AM EDT - 10 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow: Epic Growth & Operating Leverage On Full Display

May 28, 2025, 3:20 PM EDT - 10 months ago

Harrow: Epic Growth & Operating Leverage On Full Display

Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 11 months ago

Harrow to Present at Two Investor Conferences in May

HubAllianceModern
HubAllianceModern Mar. 21 at 6:30 PM
$HROW biotech, just observing calmly.
0 · Reply
Aombeus
Aombeus Mar. 21 at 6:52 AM
$HROW
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 21 at 5:39 AM
$HROW RSI: 13.38, MACD: -3.7069 Vol: 8.36, MA20: 41.00, MA50: 44.58 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
azv134
azv134 Mar. 20 at 9:22 PM
THIS MARKET CRASH IS PERFECT TO MAKE THE FOLLOWING STOCKS MY CORE POSITIONS IN 2026 $ABEO $HROW $AQST $OCUL Aiming for ~ 15% allocation of my portfolio in each company.
0 · Reply
Fullback
Fullback Mar. 20 at 8:09 PM
$HROW Still seems to be steady selling pressure. Almost 1M shares traded today, ~ 1/3 of it in the last 1/2hr or so.
1 · Reply
flash9875
flash9875 Mar. 20 at 7:38 PM
$HROW f you trump
0 · Reply
Aombeus
Aombeus Mar. 20 at 7:15 PM
$HROW
0 · Reply
AceBeck
AceBeck Mar. 20 at 1:53 PM
$HROW Oversold?
1 · Reply
Finnish_boy
Finnish_boy Mar. 20 at 11:50 AM
$HROW ETON market cap 550M.. looks nice value. But my other stocks are enough great so i have to look at this later. I almost bought TMDX at $111 but i focus now on my stocks. Have to diversify my portfolio later this year.
0 · Reply
Finnish_boy
Finnish_boy Mar. 20 at 10:06 AM
$HROW HROW and indexes make new ATH by June. HROW and indexes can go couple of percentages lower but bottoms are near. Bears dont understand bigger picture. E.g if you understand NVDA it's super cheap. People talking about bubble is so stupid.
2 · Reply
Aombeus
Aombeus Mar. 20 at 7:18 AM
$HROW should be above 40 as we speak
1 · Reply
HROW200
HROW200 Mar. 20 at 2:39 AM
$HROW Mark mentioned this study in the recent earnings call. Estimated study completion date is August.
1 · Reply
am2
am2 Mar. 19 at 11:41 PM
$HROW Are there any comments here regarding the very bullish after-hours price action of the stock?
1 · Reply
Aombeus
Aombeus Mar. 19 at 3:15 PM
$HROW 10k shares are enough to make a few million
1 · Reply
Aombeus
Aombeus Mar. 19 at 3:04 PM
$HROW
0 · Reply
Aombeus
Aombeus Mar. 19 at 1:54 PM
$HROW
0 · Reply
Alberthansson02
Alberthansson02 Mar. 19 at 1:52 PM
$HROW Will we see under 30? Will load up like a crazy person if we get close to 30…
0 · Reply
flash9875
flash9875 Mar. 19 at 1:26 PM
$HROW Trump needs to be removed from office
0 · Reply
MakeSomeMoneyToday
MakeSomeMoneyToday Mar. 19 at 12:42 PM
$HROW HC Wainwright & Co. analyst Yi Chen reiterates Harrow (NASDAQ:HROW) with a Buy and maintains $70 price target.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 18 at 10:30 PM
$HROW Share Price: $34.49 Contract Selected: Oct 16, 2026 $35 Calls Buy Zone: $5.70 – $7.04 Target Zone: $9.88 – $12.07 Potential Upside: 64% ROI Time to Expiration: 211 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Aombeus
Aombeus Mar. 18 at 4:35 PM
$HROW added in a big way
0 · Reply
HROW200
HROW200 Mar. 18 at 2:26 PM
$HROW Cyclosporine is used to prevent rejection in kidney transplants so it does make sense to use Vevye in corneal transplant patients. Corneal grafts used to treat fungal keratitis or fungal scarring have a high risk of rejection. We’re only talking 2,000-4,000 a year. If Vevye became the standard of care for all corneal graft procedures, then we have 40,000.
1 · Reply